Prodrugs of heteroaryl compounds
View Patent ↗The present invention provides hydrophobic prodrugs of bases, nucleosides, and nucleotides as well as methods of using the prodrugs as antiviral and anti-cancer chemotherapeutic agents.
1. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I:
wherein
a is either 0 or 1;
b is either 0 or 1;
the dashed line represents a double bond between C* and N when a is 0;
R 1 is a structure according to Formula II:
wherein
the dashed line represents a double bond between C a and C b ;
R 9 , R 10 and R 11 members independently selected from H, —OH, —OR 12 , —NH 2 , —NO 2 , —SO 2 NH 2 , N 3 , halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7-membered cycloalkyl, substituted or unsubstituted 5- to 7-membered heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
R 2 is a member selected from (═O) and NR 7 R 8 , such that when R 2 is (═O), b is 0, and when R 2 is NR 7 R 8 , b is 1;
R 4 is a member selected from H, halogen, OR 3 , NR 7 R 8 , nitrile, and substituted and unsubstituted (C 1 -C 5 )alkyl;
R 6 is a member selected from H, halogen, substituted or unsubstituted O-alkyl, NR 3 R 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7-membered cycloalkyl, substituted or unsubstituted 5- to 7-membered heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
R 7 , R 8 and R 5 are members independently selected from H, OR 3 , NR 3 R 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7-membered cycloalkyl, substituted or unsubstituted 5- to 7-membered heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
R 3 is independently selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted acyl;
wherein R 7 and R 8 together with the nitrogen to which they are joined optionally form a substituted or unsubstituted 5- to 7-membered ring;
wherein R 8 and R 5 together with the atoms to which they are joined optionally form a substituted or unsubstituted 5- to 7-membered ring;
wherein R 5 and R 6 together with the atoms to which they are joined optionally form a substituted or unsubstituted 5- to 7-membered ring;
wherein R 12 is selected from an amino acid and a peptide comprising between 2 and 5 amino acids;
wherein R 9 and R 10 together with the atoms to which they are joined optionally form a substituted or unsubstituted 5- to 7-membered ring;
wherein R 10 and R 11 together with the atoms to which they are joined optionally form a substituted or unsubstituted 5- to 7-membered ring; and
wherein at least one member selected from R 3 , R 5 , R 7 , and R 8 , alone or together with the atom to which it is covalently bonded, is selected from carbamate and urea linkers; and
an antiviral agent, for treatment of HIV infection.
2. The composition of claim 1 , wherein the antiviral agent is a member selected from the group consisting of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PI), fusion inhibitors (FIs), integrase inhibitors, entry inhibitors, maturation inhibitors and immune-based therapeutic agents.
3. A method for treating HIV infection, the method comprising the step of administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula I:
wherein
a is either 0 or 1;
b is either 0 or 1;
the dashed line represents a double bond between C* and N when a is 0;
R 1 is a structure according to Formula II:
wherein
the dashed line represents a double bond between C a and C b ;
R 9 , R 10 and R 11 are members independently selected from H, —OH, —OR , —NH 2 , —NO 2 , —SO 2 NH 2 , N 3 , halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7-membered cycloalkyl, substituted or unsubstituted 5- to 7-membered heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
R 2 is a member selected from (═O) and NR 7 R 8 , such that when R 2 is (═O), b is 0, and when R 2 is NR 7 R 8 , b is 1;
R 4 is a member selected from H, halogen, OR 3 , NR 7 R 8 , nitrile, and substituted and unsubstituted (C 1 -C 5 )alkyl;
R 6 is a member selected from H, halogen, substituted or unsubstituted O-alkyl, NR 3 R 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7-membered cycloalkyl, substituted or unsubstituted 5- to 7-membered heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
R 7 , R 8 and R 5 are members independently selected from H, OR 3 , NR 3 R 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7-membered cycloalkyl, substituted or unsubstituted 5- to 7-membered heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
R 3 is independently selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted acyl;
wherein R 7 and R 8 together with the nitrogen to which they are joined optionally form a substituted or unsubstituted 5- to 7-membered ring;
wherein R 8 and R 5 together with the atoms to which they are joined optionally form a substituted or unsubstituted 5- to 7-membered ring;
wherein R 5 and R 6 together with the atoms to which they are joined optionally form a substituted or unsubstituted 5- to 7-membered ring;
wherein R 12 is selected from an amino acid and a peptide comprising between 2 and 5 amino acids;
wherein R 9 and R 10 together with the atoms to which they are joined optionally form a substituted or unsubstituted 5- to 7-membered ring;
wherein R 10 and R 11 together with the atoms to which they are joined optionally form a substituted or unsubstituted 5- to 7-membered ring; and
wherein at least one member selected from R 3 , R 5 , R 7 , and R 8 , alone or together with the atom to which it is covalently bonded, is selected from carbamate and urea linkers; and an antiviral agent.
4. The method of claim 3 , wherein the antiviral agent is a member selected from the group consisting of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PI), fusion inhibitors (FIs), integrase inhibitors, entry inhibitors, maturation inhibitors and immune-based therapeutic agents.
5. The method of claim 3 , wherein the antiviral agent and the compound are admixed in a pharmaceutical composition.
6. The method of claim 3 , wherein the antiviral agent and the compound are administered separately.
7. The method of claim 3 , wherein said compound has the structure:
8. The composition of claim 1 , wherein R 2 is selected from (═O), —NH 2 , and —NHOH.
9. The composition of claim 1 , wherein R 4 is selected from F, CN, —CCH, —CCMe, and CH 3 .
10. The composition of claim 1 , wherein R 1 comprises a hydroxyl moiety.
11. The composition of claim 1 , wherein R 9 , R 10 and R 11 are members independently selected from H, OH, (R 13 ) 3 SiO—, and a structure according to Formula III:
wherein each R 13 is independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7-membered cycloalkyl, substituted or unsubstituted 5- to 7-membered heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
wherein more than one R 13 together with the atoms to which they are joined optionally form a substituted or unsubstituted 5- to 7-membered ring; and
wherein R 16 , R 17 , and R 18 are independently selected from substituted and unsubstituted alkyl.
12. The composition of claim 11 , wherein R 16 , R 17 and R 18 are ethyl.
13. The composition of claim 1 , wherein R 3 , R 5 , R 7 , and R 8 are independently selected from H and a structure according to Formula IV:
wherein R 14 is selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, an amino acid, and a peptide comprising between 2 and 5 amino acids;
wherein if R 8 is a structure according to Formula IV, then R 7 is H.
14. The composition of claim 1 , wherein R 3 , R 5 , R 7 , and R 8 are independently selected from H and a structure according to Formula V:
wherein R 15 is selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, an amino acid, and a peptide comprising between 2 and 5 amino acids;
wherein if R 8 is a structure according to Formula V, then R 7 is H.
15. The composition of claim 13 , wherein R 14 is selected from substituted or unsubstituted (C 4 -C 12 )alkyl, benzyl, 2-nitro-furanyl, retinol, α-tocopherol, calciferol, vitamin K, cholesterol,
16. The composition of claim 14 , wherein R 15 is selected from substituted or unsubstituted (C 4 -C 12 )alkyl, benzyl, 2-nitro-furanyl, retinol, α-tocopherol, calciferol, vitamin K, cholesterol,
17. The composition of claim 15 , wherein R 14 is unsubstituted (C 6 -C 10 )alkyl.
18. The composition of claim 16 , wherein R 15 is unsubstituted (C 6 -C 10 )alkyl.
19. The composition of claim 13 , wherein R 2 is selected from (═O), —NH 2 , and —NHOH.
20. The composition of claim 14 , wherein R 2 is selected from (═O), —NH 2 , and —NHOH.
21. The composition of claim 15 , wherein
R 2 is selected from (═O), —NH 2 , and —NHOH; and
R 4 is selected from —F, —CN, —CCH, —CCMe, and —CH 3 .
22. The composition of claim 16 , wherein
R 2 is selected from (═O), —NH 2 , and —NHOH; and
R 4 is selected from —F, —CN, —CCH, —CCMe, and —CH 3 .
23. The composition of claim 1 , wherein R 4 is NR 7 R 8 .
24. The composition of claim 23 , wherein R 7 and R 8 are independently selected from H and a structure according to Formula IV:
wherein R 14 is selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, an amino acid, and a peptide comprising between 2 and 5 amino acids;
wherein if R 8 is a structure according to Formula IV, then R 7 is H.
25. The composition of claim 1 , wherein said compound has the structure: